Claims for Patent: 10,202,436

Summary for Patent: 10,202,436

Title:	Peptides and combination of peptides for use in immunotherapy against various tumors
Abstract:	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s):	Mahr; Andrea (Tubingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tubingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Houston, TX), Stevermann; Lea (Tubingen, DE)
Assignee:	IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:	15/917,159
Patent Claims:	1. A method of treating a patient who has cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells in the patient, wherein the cancer cells aberrantly express a peptide consisting of the amino acid sequence of SEQ ID NO: 253, wherein said cancer is selected from the group consisting of hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), chronic lymphocytic leukemia (CLL), Merkel cell carcinoma (MCC), small cell lung cancer (SCLC), Non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC). 2. The method of claim 1, wherein the T cells are autologous to the patient. 3. The method of claim 1, wherein the T cells are obtained from a healthy donor. 4. The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. 5. The method of claim 1, wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide. 6. The method of claim 1, wherein the peptide is in a complex with an MHC molecule. 7. The method of claim 1, wherein the composition further comprises an adjuvant. 8. The method of claim 7, wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid co-glycolid) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, IL-23, and interferon-beta. 9. The method of claim 5, wherein the activated T cells are expanded in vitro. 10. The method of claim 5, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide. 11. The method of claim 10, wherein the antigen presenting cell is a dendritic cell or a macrophage. 12. The method of claim 9, wherein the activated T cells are expanded in the presence of an anti-CD28 antibody and IL-12. 13. The method of claim 1, wherein the population of activated T cells comprises CD8-positive cells. 14. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, or UEC, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt and an adjuvant, wherein said peptide consists of the amino acid sequence of SEQ ID NO: 253, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, or UEC. 15. The method of claim 14, wherein the T cell response is a cytotoxic T cell response. 16. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells, wherein the activated T cells selectively recognize the cancer cells in the patient, wherein the cancer cells aberrantly express a peptide consisting of the amino acid sequence of SEQ ID NO: 253, wherein said cancer is selected from the group consisting of HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and UEC. 17. The method of claim 16, wherein the activated T cells are produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell for a period of time sufficient to activate said T cell in a peptide-specific manner. 18. The method of claim 17, wherein the antigen presenting cell is an artificial antigen presenting cell (aAPC) comprising the peptide in a complex with an MHC class I molecule and an anti-CD28 antibody loaded on the surface of the aAPC. 19. The method of claim 16, wherein the composition further comprises an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid co-glycolid) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, IL-23, and interferon-beta. 20. The method of claim 17, wherein the contacting is in vitro. 21. The method of claim 1, wherein the cancer is selected from the group consisting of NSCLC, RCC, CRC, PC, esophageal cancer, and OC. 22. The method of claim 14, wherein the cancer is selected from the group consisting of NSCLC, RCC, CRC, PC, esophageal cancer, and OC. 23. The method of claim 16, wherein the cancer is selected from the group consisting of NSCLC, RCC, CRC, PC, esophageal cancer, and OC. 24. The method of claim 14, wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid co-glycolid) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, IL-23, and interferon-beta.

Details for Patent 10,202,436

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2035-03-27